Innovation
New OHE Consulting Report Explores the Many Faces of Innovation
19 June 2012
Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version…
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento. In this publication, he explores whether R&D…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 May 2012
Just out is an OHE Research Paper that examines the issues. The authors note that diagnostics not only facilitate health gain and cost savings, but also…
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2012 activities, he recently gave…
New: Pay-for-Performance for Drugs and Incentives for Innovation
27 February 2012
Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”. Despite its intuitive…
What is the True Value of Spending on Medical Research?
13 February 2012
Over the past four years, OHE has been involved in research intended to examine more thoroughly the economic value of medical research in the UK. Understanding…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight…
The Many Faces of Innovation
1 June 2012
This report provides a clear explanation of the nature of innovation in medicines. A fully revised and expanded version of the 2005 edition, it updates the literature…
The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
1 February 2012
Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”. Despite its intuitive…